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ABSTRACT 
Objective: To derive the first systematically-calculated estimate of the relative proportion of 
males and females with autism spectrum disorder (ASD), via a meta-analysis of prevalence 
studies conducted since the introduction of the DSM-IV/International Classification of 
Diseases–10th Revision (ICD-10).  
Method: Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
guidelines were followed. We searched MEDLINE, Embase, and PsycINFO databases, and 
study quality was rated using a risk of bias tool. Random effects meta-analysis was used. The 
outcome measure that we pooled was the male-to-female odds ratio (MFOR), namely the 
odds of being male in the group with ASD compared to in the non-ASD group. In effect this 
is the ASD male-to-female ratio, controlling for the male-to-female ratio among participants 
without ASD. 
Results: Fifty-four studies were analysed, with 13,784,284 participants, of whom 53,712 had 
ASD (43,972 males and 9,740 females). The overall pooled MFOR was 4.20 (95% CI 3.84, 
4.60), but there was very substantial between-study variability (I2=90.9%). High-quality 
studies had a lower MFOR = 3.32 (95% CI [2.88, 3.84]). Studies that screened the general 
population to identify participants regardless of whether they already had an ASD diagnosis 
showed a lower MFOR = 3.25 (95% CI [2.93, 3.62]) than studies that only ascertained 
participants with a pre-existing ASD diagnosis (MFOR = 4.56, 95% CI [4.10, 5.07]). 
Conclusion: Among children meeting criteria for ASD, the true male-to-female ratio is not 
four to one, as is often assumed; rather, it is closer to three to one. There appears to be a 
diagnostic gender bias, meaning that girls who meet criteria for ASD are at disproportionate 
risk of not receiving a clinical diagnosis.  
Key words: Autism spectrum disorder; male-to-female ratio; sex difference; meta-analysis; 
epidemiology 
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INTRODUCTION 
Autism spectrum disorder (ASD) is a neurodevelopmental condition characterised by 
impairments in social reciprocity and social communication, as well as restricted, repetitive 
patterns of behaviour.1 It is highly heritable, persists across the lifespan, and affects 
approximately one percent of the population.2,3 One striking and consistent feature of ASD is 
that it is more commonly diagnosed in males than in females.1 This has motivated influential 
ideas about the nature and aetiology of ASD, such as the Extreme Male Brain,4 Female 
Protective Effect,5 and Female Autism Phenotype6 theories. Further, the widely 
acknowledged excess of males on the autism spectrum influences day-to-day clinical and 
educational practice, for example when clinicians and teachers make decisions about whether 
a child has autistic symptoms based partly on their gender.7 As such, it is important to have a 
systematically derived, precise estimate of the male-to-female ratio in ASD in order to guide 
research and practice.   
The DSM-5 states that “autism spectrum disorder is diagnosed four times more often 
in males than in females.”1(p57) This four-to-one gender ratio is widely cited and comes from 
work that calculated the mean male-to-female ratio from population prevalence studies of 
ASD.8 Whilst such estimates are useful as a rough guide to the male-to-female ratio in ASD, 
they do not use meta-analysis to synthesise findings. As such they do not take account of 
important factors such as sample size and case ascertainment method, and so give equal 
weight to all reviewed studies irrespective of their size, design, and quality.  
Further, simple averages of gender ratios do not capture a key feature of the ASD gender 
ratio; namely, its substantial variability across studies. Even among epidemiological studies 
that implemented similar inclusion criteria and recruitment methods, ASD male-to-female 
ratios show striking variability, ranging between eight-to-one9 and two-to-one.10 This 
heterogeneity is currently little studied and therefore poorly understood. Its investigation will 
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be instructive about the true ratio of males to females with ASD, and can elucidate whether 
there are, as is often suggested, diagnostic biases against females with ASD. Specifically, it 
will be valuable to examine formally between-study variability in the ASD male-to-female 
ratio to discover whether it is influenced by the following: 
1. Study quality. If study quality is associated with variability in the ASD male-to-
female ratio, particular weight should be given to studies with the greatest 
methodological merit, as these are likely to give the most precise, valid estimates. 
2. Case-ascertainment method. Active case-finding methods involve screening a 
population-based sample in an attempt to identify all cases regardless of whether they 
have already come to clinical attention. By contrast, passive case-finding studies 
review existing databases (e.g. medical or special educational records), or contact 
parents via mass-telephone surveys, to discover who within a given population has 
received an ASD diagnosis.11 Such approaches are considered passive because they 
only pick up those who have already been officially identified. We argue that active 
methods will yield more valid estimates of the male-to-female ratio, as they are more 
likely to identify individuals with ASD, even if they have been missed by services. 
Further, comparisons of estimates from active and passive studies will be instructive 
about whether females who would meet criteria for ASD are at disproportionate risk 
of missing out on a clinical diagnosis. 
3. Date of study. Prevalence rates of ASD have increased over time, but it is unclear 
whether or not the male-to-female ratio of diagnosed cases is also changing.12  
4. Participant IQ. It is commonly suggested that IQ affects the ASD male-to-female ratio, 
with the proportion of males often observed to be higher amongst people with higher 
IQ.13 However, to date, this has not been formally tested using meta-analysis.  
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5. Participant age. Females with ASD tend to receive their diagnosis later than males,14 
so it is possible that the male-to-female ratio will be higher in younger samples.  
In summary, the present systematic review seeks to investigate the relative proportion of 
males and females on the autism spectrum via a meta-analysis of published prevalence 
studies. The initial aim is to ascertain the first systematically-derived, weighted, pooled 
estimate of the male-to-female ratio of ASD. The second aim is to enhance understanding of 
the true ASD male-to-female ratio by investigating the effects of: (1) study quality; (2) active 
versus passive case ascertainment; (3) date of study; (4) participant IQ; (5) participant age.  
METHOD 
We followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) guidelines for systematic reviews. 
Eligibility Criteria 
Studies with the following characteristics were eligible for this systematic review: 
1. Investigation of ASD prevalence within a general population sample of at least 1,500.  
2. Diagnosis of ASD based on DSM-5, DSM-IV-TR, DSM-IV or International 
Classification of Diseases–10th Revision (ICD-10) criteria. This was designed to 
maximise generalizability to current practice. 
3. Information provided on number of females and males with ASD, as well as overall 
size of population studied, to enable calculation of the primary outcome measure for 
this meta-analysis.  
4. Year(s) of data collection reported. 
5. Age range of sample falls between 0 and 18 years. It was decided to exclude studies 
of prevalence in adults with ASD, as such research is currently rare; and ASD gender 
ratios for adults may be different from those in child and adolescent populations15. 
Information Sources and Search  
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Figure 1 shows the process by which papers were identified. A systematic search was 
conducted on 23/09/2015 using the MEDLINE, Embase and PsychINFO databases. These 
searches combined keywords, MeSH terms, and text words “autism” OR “pervasive 
developmental disorde*” OR “Asperger*” AND “epidemiology” OR “prevalence.” Also, the 
reference lists of relevant articles and previous reviews of ASD prevalence were obtained and 
screened for any additional studies missed by the database search. Next, titles and abstracts of 
the articles identified were screened against inclusion criteria. For articles passing this 
screening stage, the full journal articles were read to determine whether they met study 
inclusion criteria. This process was conducted by the first author. To check its reliability, a 
second, blind rater (L.H.) was given a random sample of 200 of the 1,012 articles identified 
in the initial search stage, and evaluated these against our inclusion criteria. There was 
perfect (i.e., 100%) agreement between the initial and second (blind) rater about which of 
these articles met inclusion criteria for this review.  
Data Extraction  
The first (R.L.) and second authors (L.H.) independently extracted data from all articles 
identified as meeting study criteria, using a coding sheet designed for the current meta-
analysis (available on request from the corresponding author). Disagreements about data 
points were discussed and resolved within the study team.  
Assessing Risk of Bias 
We used the Hoy Risk of Bias Tool (RoBT)16 for assessing methodological features 
of prevalence studies, which consists of ten items plus a summary assessment. Items one to 
four assess external validity, and items five to ten assess internal validity. Each item is scored 
“0” (risk of bias absent) or “1” (risk of bias present), so that the scale has an overall 
maximum of 10, with higher scores reflecting a greater risk of bias. To assess reliability of 
the RoBT, all studies were blind double-rated by the first and second authors. Inter-rater 
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reliability for the total RoBT score, calculated using Case 2A intra-class correlations (ICCs) 
to assess levels of absolute agreement17 was high (ICC=.93, 95% CI [.89. .96]). In order to 
derive a consensus RoBT score, any disagreements on individual items were discussed 
between the first and second authors, and if these could not be resolved in this way, the senior 
author (W.M.) was consulted.  
Data Analysis 
The outcome measure summarised in this meta-analysis was the odds ratio describing 
the odds of being male in the group with ASD compared to the odds of being male in the 
group without ASD. We call this the “male-to-female odds ratio.” In effect, this presents the 
male-to-female ratio amongst those with ASD, controlling for the male-to-female ratio 
amongst participants without ASD. This male-to-female odds ratio is a purer measure of the 
ASD gender ratio than simply calculating a male-to-female ratio for diagnosed cases, as it 
takes account of any gender imbalance in a study’s overall sample that could artificially 
inflate or depress the ASD male-to-female ratio. The STATA command ‘metan’ was used to 
conduct a random-effects meta-analysis using the DerSimonian and Laird procedure to derive 
a pooled male-to-female odds ratio and 95% CIs. The I2 squared statistic was used to measure 
between-study heterogeneity.18 An I2 value of 0% indicates no observed heterogeneity 
beyond that expected from sampling error, and larger values show increasing heterogeneity,19 
with I2 above 75% indicative of substantial heterogeneity. A Harbord Test, implemented 
using the STATA ‘metabias’ command, was used to evaluate publication bias.20  
Meta-regressions, using the STATA ‘metareg’ command, were conducted to 
investigate influences on the ASD male-to-female ratio. Study characteristic variables (risk of 
bias, case ascertainment method, date of study, IQ of those with ASD, age of sample) were 
regressed separately against the log of the male-to-female odds ratio. Where a significant 
association was found, we checked for potential confounds (i.e., other study characteristic 
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variables that were significantly associated with both the predictor and the outcome) and 
controlled for these by adding them to the model. We also present subgroup meta-analyses 
comparing studies grouped according to predictors of interest, as follows: (1) low versus 
medium/higher risk of bias; (2) passive versus active case ascertainment; (3) older (1992 to 
2001) versus more recent (2002 to 2011) studies; (4) lower IQ (>50% of those with ASD had 
intellectual disability) versus higher IQ (≤50% of those with ASD had intellectual disability); 
(5) younger (0 to 6 years) versus older (6 to 18 years) participants.  
RESULTS 
Overview 
Figure 1 depicts the process by which studies were identified. A total of 54 met 
inclusion criteria, comprising 13,784,284 participants, 53,712 of whom were diagnosed with 
ASD (43,972 males and 9,740 females). Details of each study, including total risk of bias 
score, are provided in Table S1, available online. Fourteen studies were conducted in North 
America, with 11 taking place in the United States of America21-31 and three in Canada.32-34 
Twenty-four were European, with 12 carried out in the United Kingdom,3,35-45 and the other 
13 being in Sweden,46-49 Denmark,50-52 Norway,53-55 France,10 Iceland,56 and Portugal.57 
There were 11 Asian studies, in Japan,58-60 China,61-62 Israel,63-64 Iran,65 Oman,66 South 
Korea,67 and Taiwan.68 There were two studies from South America, conducted in Aruba69 
and Venezuela,70 and two from Australia.9,52 The studies spanned a period of 19 years, 
conducted between 1992 and 2011. The average estimated ASD prevalence across all studies 
was 61.9 per 10,000 (SD=48.5, 95% CI [48.6, 75.1]). 
[Figure 1 here] 
Risk of Bias and Case Ascertainment 
Overall, the methodological quality of the reviewed studies was high. The RoBT used 
to evaluate study quality ranges from 0 to 10, with higher scores being indicative of greater 
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risk of bias (i.e., lower quality). The most common risk of bias detected was that 40 studies 
failed to demonstrate explicitly that the study’s target population was a close representation 
of the national population (RoBT Item 1). Also, a majority of studies (n=37) did not use an 
assessment instrument with well-established psychometric properties to identify ASD cases 
(Item 7).  None of the studies scored above five on the RoBT (median = 3, mean = 3.15, 
SD=1.29).  For the risk of bias subgroup meta-analysis, we grouped 17 studies as having a 
low risk of bias (scoring 0-2, i.e., below the average score), and 37 studies as having a 
medium or higher risk of bias (scoring 3-5). Twenty studies used active case ascertainment, 
with the remaining 34 employing passive case ascertainment.  
Age and IQ of Young People With ASD 
Only half (n=27/54) of studies reported the average age of the participants with ASD 
they identified (mean=7.45 years, SD=2.91). All studies reported an age range for their 
sample. To avoid missing data, we estimated the average age for each study by taking a 
midpoint between the minimum and maximum of this age range. For the 27 studies for which 
precise age data were available, this method provided an excellent estimate of the individuals 
with ASDs’ reported average age (r=.98, p<.001). There were 24 studies that provided 
sufficient information for the proportion of participants with an intellectual disability (i.e., IQ 
70 or below) to be derived. Amongst these, the mean percentage of people with ASD who did 
not have an intellectual disability was 51.75% (SD = 19.80). For the subgroup meta-analyses, 
we categorised studies into higher IQ (at least 50% of individuals with ASD had IQ above 70, 
n=14) and lower IQ (less than 50% had IQ above 70, n=10) groups. 
ASD Male-to-Female Odds Ratio in ASD 
Inspection of a funnel plot and the Harbor test did not suggest evidence of publication 
bias (p=.458). As shown in Table 1, the overall pooled male-to-female odds ratio was 4.20 
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(95% CI [3.84, 4.60]). The I2 statistic was 90.9%, indicating a large amount of between-study 
heterogeneity.  
[Table 1 here] 
Influences on the ASD Male-to-Female Odds Ratio 
Table 2 shows the results of meta-regressions investigating which study 
characteristics were associated with variability in the ASD male-to-female ratio. Risk of bias, 
case ascertainment method (active v. passive), proportion of participants with ASD with 
intellectual disability and date of study were each individually associated with the male-to-
female odds ratio. However, as is shown in Table 2, once we identified and controlled for 
confounds, only IQ and case ascertainment method (active v. passive) remained significant 
predictors of the ASD male-to-female ratio.  
  The subgroup meta-analyses presented in Table 2 demonstrate the nature of these 
effects. Studies that identified a higher proportion of ASD cases with a co-occurring 
intellectual disability showed a lower male-to-female odds ratio. Active case ascertainment 
studies showed a lower male-to-female ratio than those relying on passive case ascertainment, 
an effect that is depicted in Figure 2. For the studies employing passive case ascertainment, 
the I2 statistic indicated substantial and significant heterogeneity. By contrast, no significant 
heterogeneity was observed for the active case ascertainment studies. 
[Table 2 here] 
 [Figure 2 – here] 
We sought to explore whether the lower male-to-female ratio in active studies was 
driven by the ascertainment of more females than in passive studies. We did this by 
examining, post hoc, the raw numbers of female and male participants with ASD identified 
by active and passive studies. Overall, active studies identified, on average, 65.6 cases per 
10,000 (SD=63.8, 95% CI [35.7, 95.4], compared to 59.7 [SD=37.8, 46.5, 72.9]) for passive 
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studies. Active studies identified, on average, 24.1 females per 10,000 females (SD=22.5, 95% 
CI [13.6, 34.6]), whereas passive studies identified 20.3 (SD=14.9, 95% CI [15.1, 25.5]). The 
opposite pattern was observed for males: active studies (M=81.1, SD=62.2, 95% CI [51.9, 
110.2]) tended to identify fewer males per 10,000 males than did passive ones (M=95.4, 
SD=59.3, 95% CI [74.7, 116.1]).   
DISCUSSION 
We conducted the first meta-analysis of the ASD male-to-female ratio based on a 
systematic review of epidemiological prevalence studies, reported according to PRISMA 
guidelines. The overall weighted male-to-female odds ratio (4.20, 95% I [3.84, 4.60]), 
derived from 54 prevalence studies, was consistent with DSM-5’s assertion that amongst 
diagnosed cases, there are four males for every female on the autism spectrum.1 However, 
there was significant and very substantial variability amongst the 54 studies, which calls into 
question the validity of this overall estimate of the male-to-female ratio in ASD.  
A different picture emerged when we only looked at studies likely to yield the most 
valid estimates of the male-to-female odds ratio, namely those with the highest 
methodological quality (3.32, 95% CI [2.88, 3.84]) and those that used active case-
ascertainment methods (3.25, 95% CI [2.92, 3.61]). In these subgroups, male-to-female odds 
ratios were lower, and there was consistency between studies, with no significant 
heterogeneity observed. Accordingly, we argue that the current consensus that in ASD there 
is a 4-to-1 male-to-female ratio is inaccurate: the true male-to-female ratio for ASD is lower, 
below 3.5-to-1.  
The contrast between active and passive case ascertainment studies is especially 
instructive. In studies that actively sought cases of ASD, regardless of whether they had 
already been identified by clinical or educational services, there were on average 24 girls per 
100 cases of ASD (calculated from the male-to-female odds ratio of 3.25). By contrast, in 
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passive studies, which only identify cases if they have already been diagnosed by services, 
there were 18 females per 100 ASD cases. This could arise because there are girls in the 
general population who, if assessed, would meet criteria for ASD, but who do not in practice 
receive a clinical diagnosis. Consistent with this interpretation is our observation that active 
studies tended to identify more female ASD cases than did passive studies. Our findings 
compliment and extend evidence elsewhere that suggests girls with autism are at greater risk 
than boys of having their ASD overlooked,71 misdiagnosed,7,72 or identified late.14 It is also 
notable that the lower male-to-female ratio in active studies was partially driven by a lower 
prevalence of male ASD cases, compared to passive case ascertainment studies. One possible 
interpretation of this is that active studies were more liable to miss male cases. An alternative 
interpretation is that passive studies, which rely on pre-existing diagnoses, over-estimate the 
prevalence of ASD in males.  
There is a need to formulate and counter the gender bias that leads to some girls with 
autism missing out on a timely diagnosis and the accompanying support. One likely influence 
is the female autism phenotype, a female-specific autism presentation that is subtly distinct 
from conventional conceptualisations of the disorder.12 In particular, compared to males, 
females with autism are less likely to show overt restricted interests, which would reduce the 
chances of their autism being identified.73 Further, there is some emerging evidence that 
females are more likely to mask their autistic difficulties, via a process known as 
camouflaging, making timely, accurate diagnosis more challenging.7,12 Another factor 
potentially contributing to the diagnostic bias could be key professionals (teachers, family 
doctors, paediatricians, psychiatrists, psychologists, etc.) holding gender stereotypes that 
ASD is a male disorder, reducing their sensitivity to autistic symptoms when they occur in 
females.7 Future research should address whether the diagnostic bias against females can be 
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reduced by increasing knowledge of the female autism phenotype, and conveying this 
information to diverse professionals involved in case identification. 
We found evidence for a diagnostic bias against girls who meet criteria for ASD. It 
has been proposed that an additional, nosological bias exists, whereby some females who 
have severe autistic traits (i.e. social, communication, sensory, and flexibility difficulties) fail 
to meet diagnostic criteria for ASD because these lack sensitivity to the female phenotype.12 
Evidence for this idea comes from the contrast between the male-to-female ratio we observed 
for diagnosable cases (a little over three-to-one) and the male-to-female ratio for people who 
score high for autistic traits on parent-report measures, which is commonly observed to be 
two-to-one or lower.74,75 Thus there are a disproportionate number of females who score high 
on measures of autistic traits, but who do not, even if carefully assessed, have ASD according 
to current diagnostic criteria. It is important to study such individuals, to discover if they 
really do have ASD that is being missed by male-centric diagnostic criteria, or whether 
instead their high scores on measures of autistic traits actually reflect different, non-autistic 
difficulties, such as anxiety, depression, or low IQ.76  
We found that lower IQ was associated with a lower male-to-female ratio.13 This 
result should be treated with caution, given that it is based on only the subgroup of studies 
(24/54) that provided sufficient IQ information. Further, this systematic review was not 
designed to engage fully with the challenges of measuring IQ amongst people with autism, 
and of assessing autism amongst people with intellectual disability. Nevertheless, our finding 
of there being proportionally more females in lower-IQ ASD samples does accord with other 
observations in clinical samples.13 It could arise because IQ is more protective against ASD 
in females than in males, thus making females with normal-range IQ and diagnosable ASD 
relatively rare.76 An alternative explanation is that high-functioning females with ASD are 
“flying under the radar,” their difficulties especially likely to be missed by current diagnostic 
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rubric and methods, due to them having a subtler, female-specific phenotype; and a greater 
capacity to camouflage their difficulties.77,78  
It is important to acknowledge that our findings are exclusively based on studies using 
DSM-IV, DSM-IV-TR, and ICD-10 criteria, as there are not yet DSM-5 ASD prevalence 
studies in the literature. Some have expressed concern that the changes to ASD diagnostic 
criteria ushered in by the publication of DSM-5 may have reduced their sensitivity to females 
with the condition, thus further inflating the male-to-female ratio of diagnosed cases.79 
However, empirical work has tended to contradict this idea by showing a similar male-to-
female ratio for cases identified by DSM-IV and DSM-5 criteria.80,81 Therefore, it is likely 
that our findings generalise to samples diagnosed according to DSM-5 rules, but it will be 
important to continue to monitor the gender ratio as DSM-5-based epidemiological studies 
are published. We only included studies of childhood and adolescence. As the literature on 
adult autism prevalence grows, it will be valuable to include this in future reviews. One 
possibility is that the male–female ratio diminishes in adulthood, as women with ASD who 
were missed in childhood refer themselves for assessment and self-report symptoms.15  
Whilst we have argued that the male-to-female ratio in ASD is lower than previously 
assumed, it is worth stating that our findings clearly confirm the basic fact that males are 
more vulnerable to ASD than are females. This underlines the value of research that seeks to 
explain greater male vulnerability, for example by considering the role of sex hormones4 and 
sex effects on genetic risk.5 Nevertheless, this meta-analysis supports the view, expressed by 
members of the autism community82 and by clinicians,83 that there is a need to improve 
systems for the timely detection of ASD in females.  
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Figure Captions 
Figure 1. Flow diagram of study selection, following Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Note: ASD = autism 
spectrum disorder; ICD-10 = International Classification of Diseases–10th Revision. 
Figure 2. Male-to-female odds ratio in autism spectrum disorder for active versus passive 
case ascertainment. Note: weights are from random effects analysis. OR = odds ratio.
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Table 1 –Subgroup Meta-Analyses of Male-to-Female Odds Ratio (OR) in Autism Spectrum Disorder 
    Heterogeneity 
Analysis N of 
studies 
Pooled 
OR 
95% CIs χ2  p I
2
 
       
All studies 54 4.20 3.84 – 4.60 585.19 <.001 90.9% 
Risk of bias       
Low risk of bias 17 3.32 2.88 – 3.84 19.14 .260 16.4% 
Higher risk of bias 37 4.41 3.99 - 4.89 544.39 <.001 93.4% 
Case ascertainment       
Active 20 3.25 2.93- 3.62 16.43 .628 0.0% 
Passive 34 4.56 4.10 – 5.07 540.73 <.001 93.9% 
Average age of participants       
0 to 6 years 14 4.04 3.56-4.59 22.35 0.050 41.8% 
>6 years to 18 years 40 4.26 3.83 - 4.74 562.47 <.001 93.1% 
Intellectual disability       
At least half with IQ 70 or below 10 3.10 2.50 - 3.85 23.12 0.006 61.1% 
Less than half with IQ 70 or below 14 4.25 3.33 - 5.43 68.62 <.001 81.1% 
Date of study       
1992 to 2001 17 3.51 2.90 - 4.26 56.90 <.001 71.5% 
2002 to 2011 37 4.45 4.01 - 4.94 506.56 <.001 92.9% 
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Table 2 - Meta-Regressions Investigating Study Characteristics That Predict Variability in the Male-to-Female Odds Ratio (OR) 
  Unadjusted association with log 
of male-to-female OR 
Adjusted association with log of male-to-
female OR 
 N Β (SE) 
[95% CIs] 
P Β (SE) 
[95% CIs] 
P Control 
variable(s) 
       
Risk of bias total score 54 .068 (.033) 
[.001, .135] 
.046 -.001 (.043) 
[-.090, .086] 
.965 Case 
ascertainment 
Case ascertainment 
(active=1, passive=0) 
54 -.306 (.096) 
[-.499, -.112] 
.003 -.310 (.133) 
[-.577, -
.042] 
.024 Risk of bias 
total score 
Age of individuals with 
ASD 
54 .001 (.022) 
[-.044, .045] 
.971 - - - 
Proportion of individuals 
with ASD and ID  
24 .009 (.004) 
[.001, .018] 
.034 .012 (.005) 
[.002, .023] 
.021 Date of study 
Date of study (1992-
2011) 
54 .020 (.009) 
[.002, .037] 
.033 -.022 (.021) 
[-.066, .021] 
.285 Proportion 
individuals 
with ID 
 
 Note: ASD = autism spectrum disorder; ID = intellectual disability 
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Records identified through 
database searching, after removal 
of duplicates (n = 1,005) 
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Additional records identified 
through other sources 
(n = 7) 
Total records after duplicates removed 
(n = 1,012) 
Records screened 
(n = 1,012) 
Records excluded 
(n = 817) 
Full-text articles assessed 
for eligibility 
(n = 195) 
Full-text articles excluded 
(n = 141) 
-Insufficient data on number of 
male and female cases (n = 67) 
- DSM-IV or ICD-10 not used, or 
no information given on 
diagnostic criteria (n = 26) 
-Not population-based (n = 17) 
-Data already reported in 
included study (n = 11) 
-ASD prevalence not reported (n 
= 11) 
-Outside age range (n = 5) 
-Study population less than 
1,500 (n = 3) 
-Year of data collection not 
given (n = 1) 
 
Studies included in meta-
analysis 
(N = 54) 
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